. 2020 Jun 26;10:10426. doi: 10.1038/s41598-020-67133-z

Table 5.

MWM Probe trial additional performance measures.

Group	Path Length (meters)^a	Speed (m/sec)^a	Thigmotaxis (sec)^a.b	Float Time (sec)^a.b
Eu + PBS (n = 12)	13.3 (0.6)	0.222 (0.009)	16.1 (2.7)	4.0 (1.7)
Eu + EGCG (n = 11)	12.0 (0.8)	0.200 (0.014)	24.7 (3.5)	7.8 (2.4)
Ts + PBS (n = 9)	10.4 (0.8)	0.174 (0.012)	29.0 (4.5)	10.7 (3.6)
Ts + EGCG (n = 9)	9.1 (1.5)	0.152 (0.024)	36.6 (4.1)	20.2 (4.7)

Group

Path Length
(meters)^a

Speed
(m/sec)^a

Thigmotaxis
(sec)^a.b

Float Time
(sec)^a.b

Eu + PBS

(n = 12)

13.3

(0.6)

0.222

(0.009)

16.1

(2.7)

4.0

(1.7)

Eu + EGCG

(n = 11)

12.0

(0.8)

0.200

(0.014)

24.7

(3.5)

7.8

(2.4)

Ts + PBS

(n = 9)

10.4

(0.8)

0.174

(0.012)

29.0

(4.5)

10.7

(3.6)

Ts + EGCG

(n = 9)

9.1

(1.5)

0.152

(0.024)

36.6

(4.1)

20.2

(4.7)

Data for each group are shown as mean ± (SEM). Eu = euploid; Ts = trisomic; PBS/EGCG = chronic gavage treatment.

^aMain effect of genotype.^bMain effect of treatment.